Australian pharmaceutical firm Hatchtech has appointment Timothy Waugh as chief executive.
Waugh has worked in the pharmaceutical industry for 27 years and has spent the last 10 years with Roche in the US as a divisional vice president.
Paul Kelly, Hatchtech’s chairman, said: ‘Tim’s skill set and extensive experience will be a strong addition and complement those existing in the company. The Board is confident this management team will serve us well as we take the company into the next stage of developing and commercialising DeOvo for the global marketplace.’
DeOvo is a topical formulation of a known metalloprotease inhibitor and offer the potential for a head lice control treatment that requires only one application.
Waugh said he looks forward to working with Hatchtech’s Board and management team as it review the results of the Phase IIb study and plan for the next stages of its clinical development.
Waugh will join the Board of Hatchtech and will be based in New Jersey, US.
Hatchtech appoints Tim Waugh as ceo
Formerly with Roche in the US as a divisional vice president
You may also like
Drug Delivery
SCHOTT Pharma and SHL Medical pre-validate polymer cartridge platform for large-volume autoinjectors
SCHOTT Pharma has pre-validated its ISO-standardised TOPPAC polymer cartridge for compatibility with SHL Medical’s large-volume Maggie autoinjector platform. The collaboration delivers a de-risked, ready-to-use solution for the safe at-home administration of large-volume therapies
Sustainability
BioDuro sites recognised with EcoVadis Gold and Silver sustainability certifications
Three of the CDMO's Chinese sites have been recognised for outstanding sustainability performance, highlighting BioDuro’s commitment to sustainability and its ongoing efforts to embed environmental and social responsibility into its business operations
Manufacturing
IMA Life-Sharp Sterile Manufacturing partnership strengthened with aseptic technology facility
Sharp's expanded facility in Massachusetts will include the installation of a fully automated IMA Life isolated filling line for Ready-To-Use (RTU) vials, addressing demand for US-based aseptic fill-finish services
Manufacturing
Cellistic launches three new iPSC-based GMP platforms to advance immuno-oncology and regenerative therapies
The three new iPSC-derived GMP manufacturing platforms, Echo-T, Echo-Cardio and Echo-Endothelial, expand the company’s Echo portfolio and are designed to improve scalability and manufacturability across immuno-oncology and regenerative medicine programmes
Manufacturing
The role of vacuum drying in battery manufacturing: From precursors to cell assembly
Lithium-ion battery manufacturers place enormous emphasis on material purity, structural integrity, and process control. Vacuum drying, used at both the precursor and electrode stages, has become an important step in achieving these performance and safety targets. Let’s explore where and how vacuum drying fits into modern battery production and how Powder Systems Ltd’s tray drying technology supports this growing need
Drug Delivery
Bio-Sourcing and Zerion Pharma secure Eurostars funding to develop HER2 oral monoclonal antibody
The pair have been awarded a €1.3m Eurostars grant to develop an oral formulation of the anti-HER2 monoclonal antibody trastuzumab for breast cancer, combining Bio-Sourcing’s BioMilk platform with Zerion’s Dispersome technology to advance the candidate through preclinical development